The acquisition would give Kerry additional technology to create lactose-free and reduced-sugar dairy products.
Kerry Group plc (Tralee, Ireland) announced plans to acquire part of the global lactase enzyme business belonging to Chr. Hansen Holding A/S and Novozymes A/S.
“The acquisition is subject to European Commission approval of Kerry as a buyer and forms part of the Novozymes and Chr. Hansen merger-approval process,” Kerry’s press release notes.
The acquisition would boost Kerry’s enzyme technology to create lactose-free and reduced-sugar dairy products, the firm says. Kerry had already acquired enzyme manufacturers c-LEcta and Enmex. This latest acquisition would further bolster the company’s biotechnology capabilities.
FDA revokes authorization to use Red No. 3 as a color additive in food or drugs
January 15th 2025FDA contends that the color additive is safe for humans but is legally obligated by the Delaney Clause of the FD&C act to revoke authorization as research shows the Red No. 3 induces cancer in rats.